Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia.
Intensity-modulated proton therapy
Intensity-modulated radiotherapy
Oropharyngeal cancer
Xerostomia
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
18
03
2020
revised:
23
03
2021
accepted:
28
03
2021
pubmed:
12
4
2021
medline:
28
7
2021
entrez:
11
4
2021
Statut:
ppublish
Résumé
To determine rates of xerostomia after intensity-modulated radiotherapy (IMRT) or intensity-modulated proton therapy (IMPT) for oropharyngeal cancer (OPC) and identify dosimetric factors associated with xerostomia risk. Patients with OPC who received IMRT (n = 429) or IMPT (n = 103) from January 2011 through June 2015 at a single institution were studied retrospectively. Every 3 months after treatment, each patient completed an eight-item self-reported xerostomia-specific questionnaire (XQ; summary XQ score, 0-100). An XQ score of 50 was selected as the demarcation value for moderate-severe (XQs ≥ 50) and no-mild (XQs < 50) xerostomia. The mean doses and percent volumes of organs at risk receiving various doses (V5-V70) were extracted from the initial treatment plans. The dosimetric variables and xerostomia risk were compared using an independent-sample t-test or chi-square test. The median follow-up time was 36.2 months. The proportions of patients with moderate-severe xerostomia were similar in the two treatment groups up to 18 months after treatment. However, moderate-severe xerostomia was less common in the IMPT group than in the IMRT group at 18-24 months (6% vs. 20%; p = 0.025) and 24-36 months (6% vs. 20%; p = 0.01). During the late xerostomia period (24-36 months), high dose/volume exposures (V25-V70) in the oral cavity were associated with high proportions of patients with moderate-severe xerostomia (all p < 0.05), but dosimetric variables regarding the salivary glands were not associated with late xerostomia. IMPT was associated with less late xerostomia than was IMRT in OPC patients. Oral cavity dosimetric variables were related to the occurrence of late xerostomia.
Sections du résumé
BACKGROUND AND PURPOSE
To determine rates of xerostomia after intensity-modulated radiotherapy (IMRT) or intensity-modulated proton therapy (IMPT) for oropharyngeal cancer (OPC) and identify dosimetric factors associated with xerostomia risk.
MATERIALS AND METHODS
Patients with OPC who received IMRT (n = 429) or IMPT (n = 103) from January 2011 through June 2015 at a single institution were studied retrospectively. Every 3 months after treatment, each patient completed an eight-item self-reported xerostomia-specific questionnaire (XQ; summary XQ score, 0-100). An XQ score of 50 was selected as the demarcation value for moderate-severe (XQs ≥ 50) and no-mild (XQs < 50) xerostomia. The mean doses and percent volumes of organs at risk receiving various doses (V5-V70) were extracted from the initial treatment plans. The dosimetric variables and xerostomia risk were compared using an independent-sample t-test or chi-square test.
RESULTS
The median follow-up time was 36.2 months. The proportions of patients with moderate-severe xerostomia were similar in the two treatment groups up to 18 months after treatment. However, moderate-severe xerostomia was less common in the IMPT group than in the IMRT group at 18-24 months (6% vs. 20%; p = 0.025) and 24-36 months (6% vs. 20%; p = 0.01). During the late xerostomia period (24-36 months), high dose/volume exposures (V25-V70) in the oral cavity were associated with high proportions of patients with moderate-severe xerostomia (all p < 0.05), but dosimetric variables regarding the salivary glands were not associated with late xerostomia.
CONCLUSION
IMPT was associated with less late xerostomia than was IMRT in OPC patients. Oral cavity dosimetric variables were related to the occurrence of late xerostomia.
Identifiants
pubmed: 33839202
pii: S0167-8140(21)06176-4
doi: 10.1016/j.radonc.2021.03.036
pmc: PMC8349568
mid: NIHMS1692736
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-39Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA258827
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1055-69
pubmed: 15990009
Radiother Oncol. 2014 Oct;113(1):77-83
pubmed: 25443861
J Craniomaxillofac Surg. 2017 Apr;45(4):595-600
pubmed: 28256385
Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):147-54
pubmed: 14697432
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):582-9
pubmed: 21277695
Radiother Oncol. 2011 Dec;101(3):376-82
pubmed: 21663988
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):751-60
pubmed: 17560735
Radiat Oncol. 2007 Jan 05;2:3
pubmed: 17207274
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):1007-14
pubmed: 22056067
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):966-74
pubmed: 17145527
Am J Clin Oncol. 2007 Jun;30(3):271-7
pubmed: 17551304
Cancers (Basel). 2015 Apr 10;7(2):631-47
pubmed: 25867000
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1107-14
pubmed: 27354125
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):360-367
pubmed: 27084653
Strahlenther Onkol. 2016 Apr;192(4):232-9
pubmed: 26852243
Med Dosim. 2013 Winter;38(4):390-4
pubmed: 23916884
J Clin Oncol. 2007 Nov 10;25(32):5121-7
pubmed: 17991931
Radiat Oncol. 2016 Feb 27;11:32
pubmed: 26922239
Radiother Oncol. 2004 Aug;72(2):129-38
pubmed: 15297132
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):941-7
pubmed: 22975604
Radiother Oncol. 2013 Nov;109(2):311-6
pubmed: 23953752
Virulence. 2015;6(3):244-8
pubmed: 25654476
Radiother Oncol. 2012 Oct;105(1):101-6
pubmed: 22516776
Phys Med. 2015 May;31(3):266-72
pubmed: 25724350
Radiother Oncol. 2012 Aug;104(2):219-23
pubmed: 22809589
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):725-31
pubmed: 16199308
Lancet Oncol. 2011 Feb;12(2):127-36
pubmed: 21236730
Radiat Oncol. 2008 Jan 24;3:4
pubmed: 18218078
Head Neck. 2016 Apr;38 Suppl 1:E1886-95
pubmed: 26705956
Med Dosim. 2016 Autumn;41(3):189-94
pubmed: 27158021
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):577-87
pubmed: 10524409
Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):61-70
pubmed: 12909216
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):660-9
pubmed: 17141973
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):445-53
pubmed: 16839705
Radiother Oncol. 2012 Oct;105(1):94-100
pubmed: 22169766
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1165-1174
pubmed: 26194685
Radiother Oncol. 2016 Jul;120(1):48-55
pubmed: 27342249
J Pain Symptom Manage. 2008 Aug;36(2):141-8
pubmed: 18395402
Semin Radiat Oncol. 2003 Jul;13(3):226-34
pubmed: 12903012
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1216-24
pubmed: 20732761
Radiother Oncol. 2006 Aug;80(2):263-7
pubmed: 16916557
Lancet Oncol. 2017 May;18(5):e254-e265
pubmed: 28456587
Am J Clin Oncol. 2005 Aug;28(4):351-8
pubmed: 16062076
Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704
pubmed: 11395238
Radiother Oncol. 2017 Mar;122(3):400-405
pubmed: 28043645
Support Care Cancer. 2015 Apr;23(4):925-32
pubmed: 25236164
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):589-96
pubmed: 18793962
Adv Radiat Oncol. 2017 May 12;2(3):346-353
pubmed: 29114602
Radiother Oncol. 2016 Feb;118(2):286-92
pubmed: 26867969
Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):938-46
pubmed: 11704314
Int J Part Ther. 2017 Fall;4(2):26-34
pubmed: 31773006
Radiother Oncol. 2018 Jan;126(1):75-80
pubmed: 29229507
Tech Innov Patient Support Radiat Oncol. 2020 Jun 12;14:43-50
pubmed: 32566769
Radiother Oncol. 2018 Jan;126(1):68-74
pubmed: 28823405
Radiother Oncol. 2020 Jan;142:124-132
pubmed: 31564553
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S58-63
pubmed: 20171519
Acta Oncol. 2013 Apr;52(3):561-9
pubmed: 22708528
Radiother Oncol. 2005 Nov;77(2):164-71
pubmed: 16256229
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):846-53
pubmed: 24867532
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):925-33
pubmed: 25832685